LMR Partners’s Tempest Therapeutics TPST Stock Holding History

LMR Partners’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-32	Closed	-$145K	–	542
2017 Q2	$145K	Buy	+32	New	+$135K	0.01%	552

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

LMR Partners's TPST Position: Q3 2017 in Review

LMR Partners sold out of Tempest Therapeutics (TPST) in Q3 2017, closing a stake of 32 shares — an estimated $145K sold.

LMR Partners first reported a position in TPST in Q2 2017 and held it in 1 quarter. The position peaked at $145K in Q2 2017. 47 funds tracked by Wall St. Rank hold TPST as of Q3 2017.

LMR Partners reported no remaining Tempest Therapeutics position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 32 Tempest Therapeutics shares in Q3 2017, an estimated $145K.
LMR Partners first reported a position in Tempest Therapeutics in Q2 2017 and held it in 1 quarter.
LMR Partners's Tempest Therapeutics position peaked at $145K in Q2 2017.
47 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.